Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 7, 2017, Pages 1901-1906

  Zimenkov, Danila V ^a   Nosova, Elena Yu ^b   Kulagina, Elena V ^a   Antonova, Olga V ^a   Arslanbaeva, Liaisan R ^a   Isakova, Alexandra I ^b   Krylova, Ludmila Yu ^b   Peretokina, Irina V ^b   Makarova, Marina V ^b   Safonova, Svetlana G ^b   Borisov, Sergey E ^b   Gryadunov, Dmitry A ^a  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b Department of Surgery   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; LINEZOLID; RIBOSOMAL PROTEIN L3; RIBOSOME PROTEIN; RNA 23S; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ATPC GENE; ATPE GENE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG RESISTANT TUBERCULOSIS; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MMPR GENE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PEPQ GENE; PHENOTYPE; RPLC GENE; RPLD GENE; RRL GENE; RUSSIAN FEDERATION; RV1979C GENE; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION; PROSPECTIVE STUDY;

ACETAMIDES; ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MOSCOW; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; PROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85021822459     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx094     Document Type: Article

References (41)

1. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacteriumtuberculosis. Science 2005; 307: 223-7.
2. Palomino JC, Martin A. TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiol 2013; 8: 1071-80.
3. Huitric E, Verhasselt P, Koul A et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010; 54: 1022-8.
4. Segala E, SougakoffW, Nevejans-Chauffour A et al. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother 2012; 56: 2326-34.
5. Petrella S, Cambau E, Chauffour A et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 2006; 50: 2853-6.
6. Somoskovi A, Bruderer V, Homke R et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.Eur Respir J 2015; 45: 554-7.
7. Bloemberg GV, Keller PM, Stucki D et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis.NEngl JMed2015; 373: 1986-8.
8. Biukovic G, Basak S, Manimekalai MS et al. Variations of subunit e of the Mycobacterium tuberculosis F1Fo ATP synthase and a novel model for mechanism of action of the tuberculosis drug TMC207. Antimicrob Agents Chemother 2013; 57: 168-76.
9. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-81.
10. Milano A, Pasca MR, Provvedi R et al. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb) 2009; 89: 84-90.
11. Almeida D, Ioerger T, Tyagi S et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2016; 60: 4590-9.
12. Zhang Z, Pang Y, Wang Y et al. Beijing genotype of Mycobacteriumtuberculosis is significantly associated with linezolid resistance in multidrugresistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Agents 2014; 43: 231-5.
13. Lee M, Lee J, Carroll MW et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis.NEngl JMed2012; 367: 1508-18.
14. Ramirez-Lapausa M, Pascual Pareja JF, Carrillo Gomez R et al. Retrospective study of tolerability and efficacy of linezolid in patientswithmultidrug-resistant tuberculosis (1998-2014). Enferm Infecc Microbiol Clin 2015; 34: 85-90.
15. Wilson DN, Schluenzen F, Harms JM et al. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci USA 2008; 105: 13339-44.
16. Hillemann D, Rusch-Gerdes S, Richter E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 2008; 52: 800-1.
17. Long KS, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother 2012; 56: 603-12.
18. Beckert P, Hillemann D, Kohl TA et al. rplC T460C identified as a dominant mutation in linezolid-resistantMycobacteriumtuberculosis strains. Antimicrob Agents Chemother 2012; 56: 2743-5.
19. Borisov SE, Ivanushkina TN, Ivanova DA et al. [Effectiveness and safety of the bedaquiline-containing six-month chemotherapy regimens in pulmonary tuberculosis patients]. Tuberkulez i Social'no Znachimye Zabolevaniya 2015; 3: 30-49. http://elibrary.ru/item.asp?id=26142614.
20. Morozova TI, Otpuschennikova ON, Doktorova NP et al. [Experience of using bedaquiline in the treatment of pulmonary tuberculosis patients with multiple drug resistance]. Tuberk Biolezni Legkih 2016; 94: 29-35. http://tibljournal. com/en/article/1016/.
21. Ivanushkina TN, Borisov SE, Litvinova NV et al. [Linezolid in the intensive phase of chemotherapy in patientswith respiratory tuberculosis with multiple and wide drug resistance in mycobacteria]. Tuberk Biolezni Legkih 2011; 88: 34-41. http://elibrary.ru/item.asp?id=16860555.
22. Vasilyeva IA, Samoilova AG, Zimina VN et al. [Experience with linezolid used in the combination treatment of patients with tuberculosis with broad drug resistance in the pathogen]. Tuberk Biolezni Legkih 2011; 88: 17-20. http://elibrary.ru/item.asp?id=16446509.
23. Barrera L, Cooreman E, de Dieu Iragena J et al. Policy Guidance on Drug- Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. Geneva: WHO, 2008. www.who.int/tb/publications/2008/whohtmtb_2008_392/en/.
24. Sharma M, Thibert L, Chedore P et al. Canadian multicenter laboratory study for standardized second-line antimicrobial susceptibility testing of Mycobacteriumtuberculosis. JClinMicrobiol 2011; 49: 4112-6.
25. Lounis N, Vranckx L, Gevers T et al. In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M. tuberculosis. Med Mal Infect 2016; 46: 220-5.
26. Rusch-Gerdes S, Pfyffer GE, CasalMet al.Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J ClinMicrobiol 2006; 44: 688-92.
27. Long KS, Munck C, Andersen TM et al. Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and crossresistance. Antimicrob Agents Chemother 2010; 54: 4705-13.
28. Lange C, Abubakar I, Alffenaar JW et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.Eur Respir J 2014; 44: 23-63.
29. Zhang S, Chen J, Cui P et al. Identification of novelmutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2015; 70: 2507-10.
30. Wade MM, Volokhov D, Peredelchuk M et al. Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotidemicroarray. DiagnMicrobiol Infect Dis 2004; 49: 89-97.
31. Georghiou SB, Magana M, Garfein RS et al. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012; 7: e33275.
32. Andries K, Villellas C, Coeck N et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014; 9: e102135.
33. Torrea G, Coeck N, Desmaretz C et al. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system. J Antimicrob Chemother 2015; 70: 2300-5.
34. Chernyaeva EN, Shulgina MV, Rotkevich MS et al. Genome-wide Mycobacteriumtuberculosis variation (GMTV) database: a new tool for integrating sequence variations and epidemiology. BMC Genomics 2014; 15: 308.
35. Peterson EJ, Ma S, Sherman DR et al. Network analysis identifies Rv0324 and Rv0880 as regulators of bedaquiline tolerance inMycobacteriumtuberculosis. NatMicrobiol 2016; 1: 16078.
36. Hanekom M, Streicher EM, Van de Berg D et al. Population structure of mixed Mycobacterium tuberculosis infection is strain genotype and culture medium dependent. PLoS One 2013; 8: e70178.
37. Sampson SL. Strength in diversity: hidden genetic depths of Mycobacterium tuberculosis. Trends Microbiol 2016; 24: 82-4.
38. Zhang Z, Lu J, Wang Y et al. Automated liquid culture systemmisses isoniazid heteroresistance in Mycobacterium tuberculosis isolates with mutations in the promoter region of the inhA gene. Eur J Clin Microbiol Infect Dis 2015; 34: 555-60.
39. Chakravorty S, Kothari H, Aladegbami B et al. Rapid, high-throughput detection of rifampin resistance and heteroresistance in Mycobacterium tuberculosis by use of sloppymolecular beacon melting temperature coding. J Clin Microbiol 2012; 50: 2194-202.
40. Zhang D, Gomez JE, Chien JY et al. Genomic analysis of the evolution of fluoroquinolone resistance inMycobacteriumtuberculosis prior to tuberculosis diagnosis. Antimicrob Agents Chemother 2016; 60: 6600-8.
41. Eilertson B, Maruri F, Blackman A et al. High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2014; 58: 3270-5.